Clinical Trial: Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity

U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07785934) titled 'Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity' on Aug. 13.

Brief Summary: This is a Phase I, open-label, two-cohort study designed to evaluate the drug-drug interaction potential of multiple-dose UBT251 Injection in adult participants with overweight or obesity.

The primary objective of Cohort 1 is to evaluate the effect of UBT251 Injection on the pharmacokinetic (PK) profiles of metformin and warfarin. The secondary objectives of Cohort 1 are to assess the influence of UBT251 Injection on the pharmacodynamic (PD) characteristics of warfarin, to evaluate the safety of UBT251 Inje...